Charles River Laboratories Intl. Inc vs Clear Secure Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $285.72 (market cap $13.46B), while Clear Secure Inc trades at $47.01 (market cap $4.98B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.7× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | YOU | |
|---|---|---|
Market Cap | $13.46B | $4.98B |
Sector | Health | Technology |
52-Week High | $282.00 | $62.36 |
52-Week Low | $145.57 | $29.61 |
Enterprise Value | $16.30B | $4.13B |
Dividend Yield | — | 1.19% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Clear Secure (YOU) trades at $47.31, down 7.63% over 24 hours, reflecting a bearish technical trend with support near $45. Fundamentally, the company reported strong Q2 2026 earnings of $0.49 per share, beating estimates, with revenue growth to $1.0 billion projected for 2026 and a net income margin of 14.78%. Recent news highlights expansion of its CLEAR1 platform and corporate membership launches, driving investor optimism despite recent price pressure.
The outlook is mixed: robust earnings beats and strategic initiatives support growth, but high valuation ratios (P/E of 32.62) and bearish technical signals pose risks. Analysts are divided with a 44% buy rating, suggesting cautious optimism amid volatility. Key risks include execution challenges and competitive pressures in identity verification services.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →